NK1 antagonists

US7122677B2 · kind B2 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Gregory A. Reichard · Lovettsville, US
• Sunil Paliwal · Manalapan, US
• Neng-Yang Shih · Lexington, US
• Dong Xiao · Hackettstown, US
• Hon-Chung Tsui · East Brunswick Township, US
• Sapna Majmundar Shah · Jamesburg, US
• Cheng Wang · Fort Washington, US
• Michelle Laci Wrobleski · Whitehouse Station, US

Key dates

• Filing date: Nov 12, 2002
• Grant date: Oct 17, 2006
• Expiry date: Oct 28, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceuticals compositions. Methods of treatment and combinations with other agents are also disclosed.